CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Expert Answers to Clinician Questions
CCO Oncology Podcast
English - August 05, 2021 20:30 - 8 minutes - 7.4 MBCourses Education Health & Fitness Medicine essential thrombocythemia myelofibrosis oncology cme skin cancer acute myeloid leukemia kidney cancer melanoma gastrointestinal cancer prostate can Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed
In this episode, Javier Cortes, MD, PhD; Stephen R. D. Johnston, MA, FRCP, PhD; and Sara Tolaney, MD, MPH, answer questions from an audience of healthcare professionals on topics related to leveraging CDK4/6 inhibitors for HR-positive/HER2-negative early breast cancer, including:
Clinical role of Ki-67 testingCore biopsies for identifying potential benefit with neoadjuvant endocrine therapyCombining CDK4/6 inhibition with tamoxifenPresenters:
Javier Cortes, MD, PhD
Head, Breast Cancer Program
IOB Institute of Oncology
Madrid and Barcelona, Spain
Stephen R. D. Johnston, MA, FRCP, PhD
Professor of Breast Cancer Medicine
Breast Unit
Department of Medicine
Royal Marsden Hospital
London, United Kingdom
Sara Tolaney, MD, MPH
Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F Smith Center for Women’s Cancer
Director of Clinical Trials, Breast Oncology
Director of Breast Immunotherapy
Clinical Research
Senior Physician
Breast Oncology Program
Dana-Farber Cancer Institute
Boston, Massachusetts, USA
Content based on an online CME program supported by an educational grant from Lilly.
Link to full program, including downloadable slides and associated Podcast Pearls PDF:
https://bit.ly/37tfvtj